Literature DB >> 29777455

Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.

Rui Liao1, De-Wei Li1, Cheng-You Du2, Ming Li1.   

Abstract

BACKGROUND AND
PURPOSE: Chronic inflammatory response is a risk factor for hepatocarcinogenesis and recurrence. This study aimed to develop a nomogram incorporating the combined albumin-bilirubin (ALBI) and fibrosis-4 (FIB-4) scores and the peritumoral inflammation score (PIS) to predict postoperative recurrence-free survival (RFS) of hepatocellular carcinoma (HCC).
METHODS: The prognostic roles of preoperative ALBI and FIB-4 scores for HCC recurrence were investigated, and a nomogram was developed. The predictive ability of the nomogram was compared with the American Joint Commission on Cancer (AJCC) and Barcelona Clinic Liver Cancer (BCLC) staging systems for HCC. Necroinflammatory activity in the peritumoral liver tissues was evaluated by hematoxylin and eosin (H&E) staining.
RESULTS: Combined ALBI and FIB-4 was associated with PIS in the training and validation cohorts (r = 0.342 and 0.473, both P < 0.001), and all of the scores exhibited predictive value for RFS of HCC. The independent predictive factors of RFS such as AFP, tumor number, tumor size, microvascular invasion, PIS, and combined ALBI and FIB-4 were included in the corresponding nomogram. In the training cohort, the C-index of the RFS nomogram was 0.722. ROC analyses showed that the RFS nomogram had a larger AUC (0.739) than the AJCC and BCLC staging systems. These results were verified by the validation cohort.
CONCLUSIONS: The proposed nomogram incorporating PIS and combined ALBI and FIB-4 was associated with recurrence for HCC following curative hepatectomy.

Entities:  

Keywords:  Inflammation; Liver cancer; Liver cirrhosis; Relapse; Surgery

Mesh:

Substances:

Year:  2018        PMID: 29777455     DOI: 10.1007/s11605-018-3810-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  35 in total

1.  Recurrence of hepatocellular carcinoma.

Authors:  Morris Sherman
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

Review 2.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

3.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 4.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

Review 5.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

6.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Peng-Yuan Zhuang; Hong-Guang Zhu; Wei Zhang; Yu-Quan Xiong; Wei-Zhong Wu; Lu Wang; Zhao-You Tang; Hui-Chuan Sun
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

Review 7.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

8.  Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk.

Authors:  Ying-Ying Jing; Wen-Ting Liu; Shi-Wei Guo; Fei Ye; Qing-Min Fan; Guo-Feng Yu; Dan-Dan Yu; Lu Gao; Kai Sun; Zhi-Peng Han; Rong Li; Yang Yang; Qiu-Dong Zhao; Meng-Chao Wu; Hong-Yang Wang; Li-Xin Wei
Journal:  Oncotarget       Date:  2015-12-15

9.  Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma.

Authors:  Rui Liao; Han Wu; Yong Yi; Jia-Xing Wang; Xiao-Yan Cai; Hong-Wei He; Yun-Feng Cheng; Jian Zhou; Jia Fan; Jian Sun; Shuang-Jian Qiu
Journal:  J Exp Clin Cancer Res       Date:  2013-04-19

10.  Non-invasive histologic markers of liver disease in patients with chronic hepatitis B.

Authors:  Simin Dokht Shoaei; Shahnaz Sali; Mehdi Karamipour; Esmail Riahi
Journal:  Hepat Mon       Date:  2014-02-28       Impact factor: 0.660

View more
  8 in total

1.  A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study.

Authors:  Wei Qin; Li Wang; Beiyuan Hu; Shusheng Leng; Huan Tian; Huanxian Luo; Jia Yao; Xiaolong Chen; Chao Wu; Guihua Chen; Yang Yang
Journal:  J Gastrointest Surg       Date:  2018-11-16       Impact factor: 3.452

2.  HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection.

Authors:  Rui Liao; Cheng-You Du; Jian-Ping Gong; Fang Luo
Journal:  J Oncol       Date:  2018-09-20       Impact factor: 4.375

3.  Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis.

Authors:  Yi-Xin Xu; Yi-Bo Wang; Yu-Lin Tan; Cheng Xi; Xue-Zhong Xu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

4.  Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study.

Authors:  Jian Huang; Yun Yang; Yong Xia; Fu-Chen Liu; Lei Liu; Peng Zhu; Sheng-Xian Yuan; Fang-Ming Gu; Si-Yuan Fu; Wei-Ping Zhou; Hui Liu; Bei-Ge Jiang; Ze-Ya Pan
Journal:  Cancer Manag Res       Date:  2021-02-19       Impact factor: 3.989

5.  Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies.

Authors:  XinYue Zhang; Zhen Svn; MengSi Liv; MengNan Liu; YiHan Zhang; Qin Sun
Journal:  Front Med (Lausanne)       Date:  2021-11-26

6.  Development and Validation of Artificial Neural Networks for Survival Prediction Model for Patients with Spontaneous Hepatocellular Carcinoma Rupture After Transcatheter Arterial Embolization.

Authors:  Yiwen Qiu; Tao Wang; Xianwei Yang; Shu Shen; Yi Yang; Wentao Wang
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

7.  Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection.

Authors:  Rui Liao; Xu-Fu Wei; Ping Che; Kun-Li Yin; Lei Liu
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

8.  Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma.

Authors:  Rui Liao; Xing-Diao Zhang; Gui-Zhong Li; Ke-Le Qin; Xiong Yan
Journal:  J Gastrointest Oncol       Date:  2020-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.